Latest ebit for 6492.TWO: $-310M, below the Healthcare sector average of $1.9T.
Get informed when a big investor buys or sells
+ FollowAs of Jun 30, 2026
Trailing 12 months ending Jun 30, 2026
The latest EBIT for 6492.TWO is $-310M as of June 2026. That compares with $-280M in the prior-year period — down 13.8% year over year. That is below the Healthcare sector average of $1.9T. Investors often review this figure alongside Senhwa Biosciences's historical trend and sector peers before judging valuation or financial health.
Over the past year, 6492.TWO's EBIT moved from $-280M to $-310M — a 13.8% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Senhwa Biosciences's operating scale or balance-sheet position.
Against Healthcare companies, 6492.TWO currently prints $-310M for EBIT, while the sector average sits near $1.9T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Senhwa Biosciences's growth, margins, and balance sheet.
A EBIT figure of $-310M for 6492.TWO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $1.9T. Explore the charts below for those layers of context.
After noting 6492.TWO's EBIT ($-310M), review year-over-year change from $-280M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.